对抗性的治疗方法的进步
1Epilepsy Center, Cleveland Clinic, Cleveland, Ohio, USA;
Annual review of medicine
|November 12, 2024
概括
耐药性 (DRE) 影响许多患者,尽管有治疗方法. 像手术,神经调节和基因治疗等先进疗法,在药物失败时,为控制发作提供了希望.
科学领域:
- 神经学 神经学
- 发病学 (Epileptology) 是一个专业的学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 耐药性 (DRE) 影响了三分之一的患者,导致显著的发病率和死亡率.
- 当前的抗发作药物 (ASM) 具有更好的耐受性,但与较旧的药物相比,不一定具有更高的疗效.
- 对DRE的既定治疗方法包括切除性脑外科手术和激光切除,其有效性和侵入性各不相同.
研究的目的:
- 审查药物耐药性的当前和新兴治疗策略.
- 为了比较各种DRE干预措施的有效性,风险和成本.
- 突出精准医学方法在管理中的潜力.
主要方法:
- 审查关于DRE治疗的当前文献.
- 对手术,神经调节和饮食疗法的比较有效性的分析.
- 探索新兴的遗传和精准医学策略.
主要成果:
- 切除性手术是DRE中发作自由的黄金标准.
- 神经调节器件在减少发作负担方面具有可比的有效性,在现实数据中结果可变.
- 饮食疗法是有益的,特别是对于儿科遗传.
结论:
- 多式联络方式对于管理DRE至关重要,考虑到患者特定的因素.
- 神经调节和饮食疗法为非手术候选人提供了有价值的替代方案.
- 基因疗法是个性化治疗的一个有希望的前沿.
更多相关视频
05:54Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note
Published on: June 13, 2016
17.1K
06:55Author Spotlight: Unraveling Neural Communication and Circuit Interactions in Health and Disease
Published on: November 21, 2024
677
相关概念视频
Electroconvulsive Therapy
25
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
25
Antiepileptic Drugs: Glutamate Antagonists
284
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
284
Arteries of the Lower Limbs
178
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
178
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
253
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
253
Psychosis: Goals of Pharmacotherapy
104
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
104
Antiepileptic Drugs: GABAergic Pathway Potentiators
334
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
334
